Keytruda Looks Promising in Phase 2 Study of Sarcoma
Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial.
Looking for New Targets in Non-Small Cell Lung Cancer
Jonathan Riess emphasizes the importance of testing for ROS1 and TRK in patients with lung cancer so that treatment options can be explored accordingly.
New Therapies Continue to Emerge in Triple-Negative Breast Cancer
Though it is a difficult subtype to treat right now, Cynthia Ma is optimistic about emerging treatment options for triple-negative breast cancer.
Less May Mean More in Treatment of Low-Risk Breast Cancer
In treating low-risk breast cancer, adding novel agents isn't always necessary, Hope S. Rugo says.
Immunotherapy Continues to Show Promise in Treating Gastric Cancers
The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy.
HPV Test Used With SurePath Preservative Fluid Gains FDA Approval
The FDA approved the Roche cobas HPV Test for use with SurePath Preservative Fluid.
Conquering Bone Metastases in Advanced Prostate Cancer
Bone metastases often create significant problems for patients with advanced prostate cancer, according to Neal Shore.
Reviewing a New Treatment Combination for Advanced Kidney Cancer
Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).
Expert Reviews Potential of Keytruda in Head and Neck Cancer
The need for new treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is dire, says Ranee Mehra.
Refining Treatment With Immunotherapy in Melanoma
Deciding on treatment for melanoma does not have to be a guessing game, says Keith T. Flaherty.
Expert Discusses What's Next for Opdivo in Kidney Cancer
Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.
Five-Year Data Confirm Benefit of Jakafi in Myelofibrosis
Final five-year efficacy and safety data of the JAK-2 inhibitor, Jakafi, confirmed previous findings of the treatment's benefit for patients with myelofibrosis.
Stopping TKI Treatment Is Safe for Patients With Chronic Myeloid Leukemia
A recent study identified the optimal time for certain patients with CML to stop TKI treatment.
Adding Darzalex to Drug Combination Improves Outcomes in Relapsed Multiple Myeloma
When Darzalex was added to Velcade and dexamethasone, patients with relapsed multiple myeloma had a reduced risk of disease progression or death, according to a recent phase 3 trial.
At End of Life, Aggressive Cancer Treatment Often Eclipses Recommended Palliative Care
Aggressive end-of-life care is often harmful to patients and their families, yet is still so widely used.
Basket Trial Yields Responses for Molecular Testing in 12 Cancers
Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study.
Stem Cell Transplant Continues to Be the Best Option in Multiple Myeloma
Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant, compared with patients who received chemotherapy alone.
Examining the Promise of Immunotherapy in Head and Neck Cancer
Immunotherapy is showing promise for treatment of head and neck cancer who progress after chemotherapy, though there is still a long way to go, says Robert Ferris.
Immunotherapy Combination Demonstrates Promise in Melanoma
The immunotherapy combination of Opdivo and Yervoy continues to show promise as it presented overall survival benefits for patients with advanced melanoma.
When to Treat Smoldering Myeloma
A recent phase 3 trial is exploring the question of whether or not smoldering multiple myeloma needs treatment.
High Hopes for Immunotherapy Combinations in Kidney Cancer
“There are a lot of drugs, many targets, and still no cures,” says Figlin. “There is still an unmet need, despite the plethora of agents that have been approved in this space.”
Expert Discusses Preventing Recurrence in HER2-Positive Breast Cancer
In an interview with CURE, DeMichele explains the significance of the I-SPY 2 data, the advantages of Kadcyla versus standard of care and what is on the horizon for the use of Kadcyla in HER2-positive disease.
Recent Study Findings Represent "Watershed Moment" in Metastatic Bladder Cancer
Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.
Immunotherapy the Foundation of Melanoma Care, Combinations on the Horizon
An interview with Jason Luke, an assistant professor of Medicine at the University of Chicago Medicine, reveals that he thinks immunotherapy should become a main treatment for many patients with melanoma.
Examining the Role of Surgery in Kidney Cancer
As treatments for kidney cancer continue to evolve, oncologists, surgeons and patients are faced with a number of questions.
New Therapies for Multiple Myeloma Provide Optimistic Outlook
Four new drugs were approved in 2015 to treat multiple myeloma, and Sundar Jagannath is optimistic about the coming years.
Key Points: Immunotherapy for the Treatment of Melanoma
Although immunotherapies have been approved for use for patients with metastatic melanoma, doctors are still apprehensive to use them as a frontline treatment option.
Recent Imbruvica Approval Signifies CLL is Progressing Towards a Cure
The landscape for treating CLL is changing, bringing about questions and hope for a cure.
Expert Sorts Through New Tests for Prostate Cancer Detection
Several new tests for prostate cancer are on the market. When used alongside PSA screenings, they can provide a much more straightforward insight into prostate cancer risk.
Conquering Pediatric Cancer: Why Hugs for Brady Isn't Giving Up the Fight